The Handoff: This Week in Neurology News

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news. Keep your finger on the pulse of neurology with The Handoff.

The New York Times took a deep dive into SUDEP — and why the conversation around the risk is still so quiet.

– The FDA has approved Pfizer’s new opioid analgesic, Troxyca ER. The oral drug is intended to have abuse-deterrent properties, but Pfizer warns that abuse is still possible.

– Novartis and Amgen, together with BAI have begun enrolling participants in the 5-year Generation Study, which will evaluate the effects of both an active immunotherapy and oral medication in patients with 2 copies of the APOE ε4 gene.

– A Cambridge, MA-based biotech company is banking on gene therapy to help elongate the effectiveness of L-Dopa treatment for Parkinson’s disease.

– Novartis is reporting that siponimod hit its primary endpoint in the EXPAND trial for secondary progressive multiple sclerosis.

– A team from UCLA report that they’ve “jump-started” the brain of a man with severe brain injury with low-intensity focused ultrasound pulsation.

– A startup biotech company has re-emerged with a plan to resurrect a once-dead drug that targets the LRRK2 gene in Parkinson’s disease.

– Mylan NV wins one round against Teva after a court ruled that 2 of Teva’s patents for MS drug copaxone were not valid.

– Researchers from McGill University are using Microsoft’s Kinect gaming system to evaluate gait disability in patients with multiple sclerosis. Watch how the technology works below.